MIRA
INFORM REPORT
|
Report Date : |
11.12.2008 |
IDENTIFICATION
DETAILS
|
Name : |
ACIC EUROPE LIMITED |
|
|
|
|
Registered Office : |
Petousis Building, 21, Georgiou Drosini
Street, Limassol 3085 Limassol |
|
|
|
|
Country : |
Cyprus |
|
|
|
|
Date of Incorporation : |
16.07.1993 |
|
|
|
|
Com. Reg. No.: |
C56373 Nicosia |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business : |
Services, Retailers and Wholesalers of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Name & Address
NAME INQUIRED UNDER: Acic Europe Ltd
Correct Registered Name: ACIC EUROPE LIMITED
Address: Petousis
Building, 21, Georgiou Drosini street
Limassol
3085 Limassol CYPRUS
P.O.Box: 53070,
3300 Limassol
Telephone: +357-25578696
357-25-578823
Fax:
+357-25563980
Payment
Commercial Morality: Good
Financial Strength: Good
Credit Rating: Average
Risk
Legal Status
Legal Form: Private
Limited Liability Company
Private Limited Liability Company: It is
incorporated by one or more individuals or companies (maximum: 50). It is
managed by a board of directors consisted of minimum two individuals or
juridical persons. Capital is required. The shareholders are liable for the
companys debts to the extent of their respective interests in the capital. Its
shares are not to be sold through public subscription. Private Limited
Liability companies are obliged to file their accounts with the Registrar of
Companies (Company Registry).
Registration number and city: C56373 Nicosia
Registration date: 16.07.1993
Company Status
|
Registration status: 16.07.1993 -
registered company |
Principals
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Activities
Activities: Services & Retailers
& Wholesalers
Operations:
SIC
main activity
2834 Pharmaceutical Preparations
5122 Drugs, Drug Proprietaries, and Druggists' Sundries
Business Activities
Pharmaceutical Products
Industry Classifications - NAICS
» Pharmaceutical Preparation Manufacturing
» Drugs and Druggists' Sundries Merchant Wholesalers
Detailed Description of Industry Classifications
Pharmaceutical Preparation Manufacturing
NAICS # 325412 | This U.S. industry comprises establishments primarily engaged
in manufacturing in-vivo diagnostic substances and pharmaceutical preparations
(except biological) intended for internal and external consumption in dose
forms, such as ampoules, tablets, capsules, vials, ointments, powders,
solutions, and suspensions. Manufacturing uncompounded medicinal chemicals and
their derivatives--are classified in U.S. Industry 325411, Medicinal and
Botanical Manufacturing; Manufacturing in-vitro diagnostic substances--are
classified in U.S. Industry 325413, In-Vitro Diagnostic Substance
Manufacturing; and Manufacturing vaccines, toxoids, blood fractions, and
culture media of plant or animal origin (except for diagnostic use)--are
classified in U.S. Industry 325414, Biological Product (except Diagnostic)
Manufacturing.
Drugs and Druggists' Sundries Merchant Wholesalers
NAICS # 4242
Since 1993, ACIC Europe Limited has been actively developing specialty products
for API markets in Europe and other countries. They started their operations
with the global marketing of a North American based integrated manufacturer of
Lactulose and successfully partnered with European pharmaceutical companies to
introduce their product to market.
Today, ACIC Europe has grown to offer a complete range of APIs as well as
outsourcing opportunities for finished pharmaceutical specialties. Since the
advent of EU directives 2004/27 and 2004/28, ACIC Europe is the ideal source of
APIs from GMP-compliant sources. Leveraging on their US affiliate's over thirty
years experience GMP compliance, drug master files, and plant
audits/inspections with the FDA, they have the resources in place to reliably
and efficiently supply your API needs.
The ACIC team includes a full-service in-house regulatory and compliance group.
In addition to reviewing DMFs, ACIC's audit team frequently inspect facilities
so as to both prepare them for GMP compliance as well as ensure ongoing compliance
in line with the applicable regulatory changes and industry best practices.
They also offer training for API manufacturing personnel with respect to DMF
preparation and GMP compliance matters.
ACIC's Pharmaceutical Division serves those clients who are rationalizing their
production resources or want to augment their product lines by outsourcing
production of certain dosage forms. By combining a source of GMP-compliant
APIs, finished dosage production, and technology transfers, ACIC can provide
you with a competitive solution to meet your strategic needs.
Their partner companies can also offer
process optimization for novel molecules in order to advance their commercial
scale development and they are also in a position to offer certain CRO services.
Moreover, the ACIC team has built their success through the success of their
clients by providing complete solutions From Molecule to Market.
According to the person interviewed, Mrs Marilyn Koumbari, subjects' parent
company is located in Canada.
ACIC is a full service pharmaceutical and fine chemical company that provides
specialized support resources to client companies.
Furthermore, resources are drawn from our ACIC Network of both in-house
facilities and those of our established international partners.
Founded in 1974, ACIC is part of an affiliation of three pharmaceutical
companies that trade worldwide.
Over the years ACIC has proved to be a financially strong and professionally
capable company that has served both its clients and supplier partners well.
The success of ACIC has been based on the knowledge and integrity of its core
management team of veteran pharmaceutical executives led by Luciano Calenti.
Motor Vehicles
|
Not Disclosed. |
Imports
|
The subject is not engaged in any imports activities. |
Exports
|
The subject is not engaged in any exports activities. |
Agencies
|
Trade Suppliers
|
Workforce
|
Description Of Premises
Address: 163
Leontiou Street, Clerimos Building, 2nd Floor Limassol
3022 Limassol CYPRUS
Type of premises: Registered
Address
Address: Petousis
Building, 21, Georgiou Drosini street
Limassol
3085 Limassol CYPRUS
Type of premises: Premises
Type of ownership: rented
Headquarters: The
subject operates from rented offices located at the address given overleaf.
Branches: The
company in question maintains branches in Canada, Italy and USA.
81 Sinclair Boulevard, Brantford, Ontario, N3S 7X6, CANADA.
11772 West Sample Road, Coral Springs, Florida, 33065, USA.
Related Companies
|
Affiliated Company |
Bankers
|
Marfin Popular
Bank Public Company Limited - Account no. Account number is not disclosed. |
Press
|
Auditors / Accountants
|
Not Disclosed. |
Share Capital
|
||||||||||||||||||
Charges
|
None in current years. |
GENERAL COMMENTS
|
We contacted the company in question and
talked with Mrs Marilyn Koumbari who confirmed all details of this report.
However, she refused to release any financial information. Instead, she asked
for a written questionnaire in order to provide us with subjects'financial
statements. Should any additional information becomes available we will
forward them to you as soon as possible. |
Contact Person
|
Contact information
|
|
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.48.52 |
|
UK Pound |
1 |
Rs.72.62 |
|
Euro |
1 |
Rs.63.76 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)